EIF4E2
Eukaryotic translation initiation factor 4E type 2
Protein Summary
Recognizes and binds the 7-methylguanosine-containing mRNA cap during an early step in the initiation (PubMed:9582349, PubMed:17368478, PubMed:25624349). Acts as a repressor of translation initiation (PubMed:22751931). In contrast to EIF4E, it is unable to bind eIF4G (EIF4G1, EIF4G2 or EIF4G3), suggesting that it acts by competing with EIF4E and block assembly of eIF4F at the cap (By similarity).
- ENST00000258416
- ENSP00000258416
- ENSG00000135930
- ENST00000409098
- ENSP00000386996
- EIF4EL3
- 4EHP
- IF4e
- 4E-LP
- h4EHP
- EIF4EL3
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
disease perturbation | 1 | ||
kinase perturbation | 1 | ||
transcription factor binding site profile | 0.9 | ||
histone modification site profile | 0.88 | ||
transcription factor perturbation | 0.88 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 28.02 (req: < 5)
Gene RIFs: 23 (req: <= 3)
Antibodies: 384 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 28.02 (req: >= 5)
Gene RIFs: 23 (req: > 3)
Antibodies: 384 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0